
Category
SOFT GELATIN
Form
10x10
Strength
None
CAS
Nimesulide: 51803-78-2, Paracetamol: 103-90-2
Nimesulide + Paracetamol - International Quality Pharmaceutical Product
Nimesulide + Paracetamol by LARKSOIS Pharma is developed for reliable soft gelatin support in global healthcare settings. The 10x10 presentation helps optimize practical administration workflows across regulated care pathways. This formulation profile (-) is aligned with market-ready documentation and professional use standards. Every batch is handled through quality-focused systems that support consistency, traceability, and patient-centered outcomes.
This product profile is written in an international, professional format to support clear pharmaceutical decision-making. The overview helps procurement teams, healthcare professionals, and compliance stakeholders evaluate usage context quickly. LARKSOIS Pharma presents this information in a patient-safety-focused and globally readable content style.
Request QuoteImportant Information
- Category: SOFT GELATIN
- Dosage: -
- Dosage Form: 10x10
- Brand: LARKSOIS Pharma
- CAS Number(s): Nimesulide: 51803-78-2, Paracetamol: 103-90-2
- Nimesulide + Paracetamol is intended for professional pharmaceutical use with indication-specific prescribing decisions.
- Clinical suitability should be validated against patient history, co-medication profile, and therapeutic objective.
Introduction
- This product profile is written in an international, professional format to support clear pharmaceutical decision-making.
- The overview helps procurement teams, healthcare professionals, and compliance stakeholders evaluate usage context quickly.
- LARKSOIS Pharma presents this information in a patient-safety-focused and globally readable content style.
Indications
- Used based on approved clinical indication and physician diagnosis.
- May be considered where soft gelatin protocols recommend this active composition.
- Applicable in institutional, outpatient, and supervised treatment pathways where indicated.
- Supports therapeutic strategy when matched with patient-specific risk-benefit assessment.
- Indication scope may vary by market authorization and local prescribing regulation.
Maintenance
- Maintain dosing continuity as prescribed; avoid unsupervised interruption.
- Review tolerance, response, and adherence during follow-up encounters.
- Track clinical markers relevant to treatment effectiveness and safety profile.
- Reassess continuation plan when co-therapies or patient condition changes.
- Use maintenance decisions within documented clinical governance processes.
International Market Perspective
- Positioned for international markets with documentation-ready product communication.
- Supports distributor, importer, and institution-level evaluation across diverse regulatory environments.
- Content framing aligns with global expectations around safety, traceability, and quality transparency.
- Suitable for export-oriented catalog presentation where consistent product language is essential.
Dosage
General
- Use only under licensed prescriber guidance.
- Reference label and market dossier for indication-specific dosing parameters.
- Adapt dosage planning for age, organ function, and co-morbidity where required.
- Do not self-adjust frequency, quantity, or treatment duration.
Administration
- Administer exactly as advised by a qualified healthcare professional.
- Follow route, timing, and handling instructions specific to the dosage form.
- Do not alter dose frequency or administration pattern without medical review.
- Ensure patient counseling and compliance checks during each dispensing cycle.
Storage
- Store in a cool, dry environment away from direct sunlight.
- Preferred storage is generally below 25?C unless regional label states otherwise.
- Protect from humidity, contamination, and temperature excursions.
- Keep product in original packaging with batch and expiry legibility intact.
- Restrict access to children and unauthorized users.
Shelf Life
- Shelf life is defined by validated stability data and printed label timelines.
- Always verify manufacturing date, expiry date, and batch status before use.
- Do not use product beyond expiry period under any dispensing condition.
- Expired stock should be quarantined and disposed as per local pharmaceutical waste policy.
Manufacturing
- Manufactured with GMP-aligned quality systems and controlled production stages.
- Process controls emphasize identity, purity, potency, and microbial safety where applicable.
- Batch documentation supports traceability, deviation management, and recall readiness.
- Packaging and labeling workflows are designed for regulatory clarity and distribution resilience.
- LARKSOIS Pharma quality culture prioritizes reproducibility, compliance, and patient trust.
Precautions
- Use during pregnancy or lactation only if medically justified and supervised.
- Screen for known hypersensitivity to active or excipient components.
- Assess renal and hepatic function in at-risk populations before and during therapy.
- Review interaction potential with concurrent prescriptions, OTC drugs, and supplements.
- Monitor for unexpected intolerance and escalate clinically significant symptoms promptly.
- Avoid unsupervised discontinuation where continuity is essential for treatment outcomes.
Side Effects
- Mild gastrointestinal discomfort, nausea, or appetite changes may occur in some patients.
- Headache, dizziness, or transient fatigue can appear depending on individual response.
- Dermatologic responses such as rash or pruritus may indicate sensitivity and need review.
- Serious reactions are uncommon but require urgent medical evaluation when suspected.
- Adverse-event reporting and pharmacovigilance follow-up are recommended for safety monitoring.
Why Choose
- Internationally aligned product documentation and content depth.
- Clear visibility for category, dosage, form, and CAS details.
- Quality-first manufacturing narrative with GMP-oriented standards.
- SEO-ready product architecture for scalable global discoverability.
- Consistent LARKSOIS Pharma brand voice across product pages.
References
- https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications
- https://www.ema.europa.eu/en/human-regulatory-overview
- https://www.fda.gov/drugs
- https://go.drugbank.com
- https://pubchem.ncbi.nlm.nih.gov
Frequently Asked Questions
Common product and supply questions.
What is Nimesulide + Paracetamol used for?+-
Nimesulide + Paracetamol is used according to clinical diagnosis in SOFT GELATIN care. It supports evidence-based treatment goals when prescribed by qualified professionals and used with proper dosage guidance, monitoring, and patient-specific therapeutic planning.
How should Nimesulide + Paracetamol be stored?+-
Store Nimesulide + Paracetamol in a cool, dry place away from direct light and moisture, typically below 25?C unless label guidance differs. Keep original packaging sealed and check shelf life and batch details before dispensing.
What precautions apply to Nimesulide + Paracetamol?+-
Use Nimesulide + Paracetamol only under medical supervision, especially in pregnancy, lactation, pediatric, geriatric, hepatic, or renal-risk cases. Evaluate allergy history, concurrent medicines, and interaction risk before therapy initiation or maintenance continuation.
Does Nimesulide + Paracetamol have side effects?+-
Like all active pharmaceutical therapies, Nimesulide + Paracetamol may cause side effects ranging from mild gastrointestinal discomfort to medicine-specific reactions. Clinical follow-up, dose adjustment, and timely reporting of adverse events improve treatment safety outcomes.
